Gynaecological OncologyNCT07232212
Survival Outcomes of Gynecologic Oncology Patients at Assiut University
An observational study of Gynaecological Oncology, run by Assiut University.
Trial summary
This retrospective cohort study investigates survival outcomes of gynecological oncology patients treated at Assiut University Hospital between 2022 and 2025, comparing them to international benchmarks and assessing factors affecting survival. Read more about this study
- Who is it for?
- Any age, women only
- Conditions the study is for
- Gynaecological Oncology
- How many people
- 200 participants
- Where
- No sites listed yet
- Study dates
- 1 Jan 2026to 1 Feb 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- Women only
- Child, Adult, Older adult
Study population: All female patients diagnosed with gynecological cancers (including ovarian, cervical, endometrial, vulvar, and vaginal cancer) and treated at Assiut University Gynecological Oncology Department between January 1, 2022, and December 31, 2025, will be included. Patients of all ages and backgrounds are eligible. Exclusion criteria are non-gynecological cancers, metastatic cancers originating outside the gynecologic tract, incomplete medical records, or significant comorbidities that independently affect survival (e.g., advanced heart failure, severe liver or renal disease, or unrelated terminal illnesses).
Who may be able to join
- Patients diagnosed with gynecological cancers (ovarian, cervical, endometrial, vulvar, vaginal)
- Patients treated at Assiut University Gynecological Oncology Department between January 1, 2022, and December 31, 2025
- All age groups included
Who cannot join
- Patients with non-gynecological malignancies or metastatic cancers originating outside the gynecological tract
- Patients with incomplete medical records (e.g., missing pathology reports or treatment details)
- Patients with significant comorbidities independently affecting survival (e.g., advanced heart failure, severe liver or renal disease, terminal illnesses unrelated to cancer)
About this study
Official title: Survival Outcomes of Gynecological Oncology Patients at Assiut University: A Retrospective Study (2022-2025)
This retrospective cohort study investigates survival outcomes of gynecological oncology patients treated at Assiut University Hospital between 2022 and 2025, comparing them to international benchmarks and assessing factors affecting survival.
Read the detailed description
The study aims to evaluate overall survival (OS) and progression-free survival (PFS) of patients diagnosed with gynecological cancers (including ovarian, cervical, endometrial, vulvar, and vaginal cancers) and treated at Assiut University Hospital from January 1, 2022, to December 31, 2025. Using retrospective medical records and pathology reports, the study will analyze demographic, clinical, and treatment-related variables to identify factors influencing survival outcomes. Assiut University is a tertiary care center in a low-resource setting; thus, the study will also assess adherence to international oncology guidelines (e.g., ESMO, ASCO) and compare local survival rates with international standards. Statistical methods include Kaplan-Meier survival analysis and Cox proportional hazards modeling.
- Conditions
- Gynaecological Oncology
What is being measured
The primary outcome is the main question the study is designed to answer.
Overall Survival
Overall survival (OS) is defined as the duration of time from the date of cancer diagnosis or initiation of treatment until death from any cause. Patients will be censored at the date of last follow-up if alive at study end. This outcome will provide a direct estimate of survival rates among gynecological oncology patients treated at Assiut University Hospital.
Measured: 4 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Nov 2025
- Study start1 Jan 2026 (estimated)
- Primary completion1 Jan 2027 (estimated)
- Study completion1 Feb 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Gynaecological OncologyStudies of the same condition, open and under way.
- More trials run by Assiut UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 200 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Assiut University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Esraa Mohamed Farouk, Assiut University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07232212
- Sponsor's protocol ID
- Gynecological Oncology Outcome
- Status last verified
- Nov 2025
- First submitted
- 14 Nov 2025
- Last updated
- 18 Nov 2025
- Results posted
- No
Study at a glance
From the registry record, last updated by the sponsor on 18 Nov 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Survival Outcomes of Gynecological Oncology Patients at Assiut University: A Retrospective Study (2022-2025)
- ClinicalTrials.gov ID
- NCT07232212
- Acronym / sponsor ID
- Gynecological Oncology Outcome
- Conditions
- Gynaecological Oncology
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 200 participants (estimated)
- Lead sponsor
- Assiut UniversityUniversity, hospital or other
- Study start
- 1 Jan 2026 (estimated)
- Primary completion
- 1 Jan 2027 (estimated)
- Study completion
- 1 Feb 2027 (estimated)
- First posted
- 18 Nov 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This retrospective cohort study investigates survival outcomes of gynecological oncology patients treated at Assiut University Hospital between 2022 and 2025, comparing them to international benchmarks and assessing factors affecting survival.
Detailed description
The study aims to evaluate overall survival (OS) and progression-free survival (PFS) of patients diagnosed with gynecological cancers (including ovarian, cervical, endometrial, vulvar, and vaginal cancers) and treated at Assiut University Hospital from January 1, 2022, to December 31, 2025. Using retrospective medical records and pathology reports, the study will analyze demographic, clinical, and treatment-related variables to identify factors influencing survival outcomes. Assiut University is a tertiary care center in a low-resource setting; thus, the study will also assess adherence to international oncology guidelines (e.g., ESMO, ASCO) and compare local survival rates with international standards. Statistical methods include Kaplan-Meier survival analysis and Cox proportional hazards modeling.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
Who may qualify
- Sex
- Female only
- Age groups
- Child, Adult, Older adult
- Study population
- All female patients diagnosed with gynecological cancers (including ovarian, cervical, endometrial, vulvar, and vaginal cancer) and treated at Assiut University Gynecological Oncology Department between January 1, 2022, and December 31, 2025, will be included. Patients of all ages and backgrounds are eligible. Exclusion criteria are non-gynecological cancers, metastatic cancers originating outside the gynecologic tract, incomplete medical records, or significant comorbidities that independently affect survival (e.g., advanced heart failure, severe liver or renal disease, or unrelated terminal illnesses).
Key inclusion criteria (3 listed)
- Patients diagnosed with gynecological cancers (ovarian, cervical, endometrial, vulvar, vaginal)
- Patients treated at Assiut University Gynecological Oncology Department between January 1, 2022, and December 31, 2025
- All age groups included
Key exclusion criteria (3 listed)
- Patients with non-gynecological malignancies or metastatic cancers originating outside the gynecological tract
- Patients with incomplete medical records (e.g., missing pathology reports or treatment details)
- Patients with significant comorbidities independently affecting survival (e.g., advanced heart failure, severe liver or renal disease, terminal illnesses unrelated to cancer)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Overall Survival
Time frame: 4 years
Overall survival (OS) is defined as the duration of time from the date of cancer diagnosis or initiation of treatment until death from any cause. Patients will be censored at the date of last follow-up if alive at study end. This outcome will provide a direct estimate of survival rates among gynecological oncology patients treated at Assiut University Hospital.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Nov 2025.
Related trials for Gynaecological Oncology
Recruiting
Methylation Profiling in Self-Samples for Identification of (Epi)Genetic Biomarkers for Gynecological Cancers
Gynaecological Cancers, Ovarian Cancer
Enrolling by invitation
Peer Ambassador in Gyn Onc Trials
Ovarian Cancer
RecruitingPhase 3
Ferric Derisomaltose and Outcomes in the Recovery of Gynecologic Oncology: ERAS (Enhanced Recovery After Surgery)
Gynecologic Cancer, Anemia
RecruitingObservational study
GYNGHER - HER2 Expression in Gynecological Malignancies: a Brazilian Cohort
Gynaecological Cancers
Not yet recruitingObservational study
Protocol for Non-invasive Gynaecological Surveillance in Lynch Syndrome
Lynch Syndrome
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
An observational study of Gynaecological Oncology, run by Assiut University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 18 Nov 2025. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Overall Survival (time frame: 4 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Nov 2025.